ArticleCancer cell2023
ZNF683 marks a CD8
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
16.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy.Cell genomics · 2025Pooled it
- Trial
- Spatiotemporal single-cell profiling reveals T cell clonal dynamics and phenotypic plasticity in human graft-versus-host disease.Nature immunology · 2026Article
- Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities.Journal for immunotherapy of cancer · 2026Article
- Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer.Oncogene · 2026Article
- Dynamic remodeling of the pancreas immune landscape in obesity.Nature communications · 2026Article
- Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma.medRxiv : the preprint server for health sciences · 2026Article
- OT-55 reshapes tolerogenic BH3-mimetic-induced apoptosis toward immunogenic cell death in acute myeloid leukemia, potentiating PD-1/Tim-3 blockade.Cell death & disease · 2026Article
- scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Multi-omics profiling reveals tumor microenvironment characteristics linked to immunotherapy response and prognosis in non-small cell lung cancer.NPJ precision oncology · 2026Article
- The transcription factor ZNF683 marks an exhaustion-like GZMBFrontiers in immunology · 2026Article
- Multimodal tumor thermal therapy enhances antitumor immunity by expanding tumor-reactive CX3CR1⁺GPR56⁺ T cells in hepatocellular carcinoma.Theranostics · 2026Article
- Pre-treatment T cell features and immune-milieu characteristics shape treatment-induced exhaustion and resistance to Blinatumomab in B-cell acute lymphoblastic leukemia.Frontiers in immunology · 2026Article
- Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.Haematologica · 2026Article
- Single-cell and spatial landscape reveals impaired tertiary lymphoid structure maturation inFrontiers in immunology · 2026Article
- Rewiring tumor immunity via zinc finger proteins: a new frontier in cancer immunotherapy.Journal of translational medicine · 2025Review
- MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
- Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.Leukemia · 2025Article
- Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses.Science translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 10 institutions in 4 countries.
Erin M ParryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Camilla K LemvighDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.
Stephanie DengDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Nathan DangleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Neil RuthenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Binyamin A KnisbacherBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Julien BroséusInserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France; Université de Lorraine, CHRU-Nancy, Service d'hématologie Biologique, Pôle Laboratoires, 54000 Nancy, France.
Sébastien HergalantInserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France.
Romain GuièzeCHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; EA 7453 (CHELTER), Université Clermont Auvergne, 63001 Clermont-Ferrand, France.
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Wandi ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Connor JohnsonBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jaclyn M LongBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA; Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA.
Shanye YinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lillian WernerDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Annabelle AnandappaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Noelia PurroyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Satyen GohilDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA.
Pavan BachireddyDepartment of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sachet A ShuklaDepartment of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Teddy HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Joseph D KhouryDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Beenu ThakralDepartment of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Michael DickinsonPeter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Constantine TamAlfred Health, Melbourne, VIC, Australia; Monash University, Melbourne, VIC, Australia.
Kenneth J LivakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Gad GetzBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Donna NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Pierre FeugierInserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France; Université de Lorraine, CHRU Nancy, service d'hématologie clinique, Nancy, France.
Peter KharchenkoDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02215, USA.
William WierdaDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Lars Rønn OlsenDepartment of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.
Nitin JainDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: Catherine_wu@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBroad Institute · USThe University of Texas MD Anderson Cancer Center · USInserm · FRHarvard University · USMonash Health · AUTechnical University of Denmark · DKThe Royal Melbourne Hospital · AUUniversité Clermont Auvergne · FRUniversity of Nebraska Medical Center · US
Funding
ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MSingle cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4MTracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining TransformationK08CA270085 · NCI · DANA-FARBER CANCER INST · PI Erin M Parry · 2022 to 2026
$945kNCI NIH HHS K08 CA270085NCI NIH HHS P01 CA206978NCI NIH HHS R01 CA155010NCI NIH HHS R50 CA251956NCI NIH HHS U10 CA180861
Abstract
Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma originating from indolent chronic lymphocytic leukemia, is responsive to PD-1 blockade. To discover the determinants of response, we analyze single-cell transcriptome data generated from 17 bone marrow samples longitudinally collected from 6 patients with RS. Response is associated with intermediate exhausted CD8 effector/effector memory T cells marked by high expression of the transcription factor ZNF683, determined to be evolving from stem-like memory cells and divergent from terminally exhausted cells. This signature overlaps with that of tumor-infiltrating populations from anti-PD-1 responsive solid tumors. ZNF683 is found to directly target key T cell genes (TCF7, LMO2, CD69) and impact pathways of T cell cytotoxicity and activation. Analysis of pre-treatment peripheral blood from 10 independent patients with RS treated with anti-PD-1, as well as patients with solid tumors treated with anti-PD-1, supports an association of ZNF683
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseCD8-Positive T-LymphocytesGene Expression RegulationHumansImmunotherapycheckpoint blockadechronic lymphocytic leukemiaHobitimmunotherapyPD-1Richter transformationsingle-cell RNA sequencingt cellstoxZNF683
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.